Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs
Journal of Clinical Investigation · 03.06.2024 · 134 (11)
DOI: 10.1172/jci168649 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 30.04.2024. Verfasst von Dong Han und 29 weiteren Autor:innen. Beteiligte Einrichtung: Center for Personalized Cancer Therapy. Hauptthemen laut MEDLINE: Gene Expression Regulation, Neoplastic, Prostatic Neoplasms, Castration-Resistant, Receptors, Androgen. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, BLRD VA, NIAID NIH HHS.
Abstract (Originalsprache)
One critical mechanism through which prostate cancer (PCa) adapts to treatments targeting androgen receptor (AR) signaling is the emergence of ligand-binding domain–truncated and constitutively active AR splice variants, particularly AR-V7. While AR-V7 has been intensively studied, its ability to activate distinct biological functions compared with the full-length AR (AR-FL), and its role in regulating the metastatic progression of castration-resistant PCa (CRPC), remain unclear. Our study found that, under castrated conditions, AR-V7 strongly induced osteoblastic bone lesions, a response not observed with AR-FL overexpression. Through combined ChIP-seq, ATAC-seq, and RNA-seq analyses, we demonstrated that AR-V7 uniquely accesses the androgen-responsive elements in compact chromatin regions, activating a distinct transcription program. This program was highly enriched for genes involved in epithelial-mesenchymal transition and metastasis. Notably, we discovered that SOX9 , a critical metastasis driver gene, was a direct target and downstream effector of AR-V7. Its protein expression was dramatically upregulated in AR-V7–induced bone lesions. Moreover, we found that Ser81 phosphorylation enhanced AR-V7’s pro-metastasis function by selectively altering its specific transcription program. Blocking this phosphorylation with CDK9 inhibitors impaired the AR-V7–mediated metastasis program. Overall, our study has provided molecular insights into the role of AR splice variants in driving the metastatic progression of CRPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Personalized Cancer Therapy.
- Department of Biology, and.
- Department of Mathematics, University of Massachusetts Boston, Boston, Massachusetts, USA.
- Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Cell and Cancer Biology, College of Medicine and Life Sciences, The University of Toledo, Toledo, Ohio, USA.
- Department of Cell & Developmental Biology, Weill Cornell Medical College, New York, New York, USA.
Förderung
- NCI NIH HHS
- BLRD VA
- NIAID NIH HHS
- VA
- NIH/NCI
- DOD Prostate Cancer Research Program
Zitieren
APA
Han, D., Labaf, M., Zhao, Y., Owiredu, J., Zhang, S., Patel, K., Venkataramani, K., Steinfeld, J. S., Han, W., Li, M., Liu, M., Wang, Z., Besschetnova, A., Patalano, S., Mulhearn, M. J., Macoska, J. A., Yuan, X., Balk, S. P., Nelson, P. S., …, & Cai, C. (2024). Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs. Journal of Clinical Investigation, 134(11). https://doi.org/10.1172/jci168649
Vancouver
Han D, Labaf M, Zhao Y, Owiredu J, Zhang S, Patel K, et al. Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs. Journal of Clinical Investigation. 2024;134(11). doi:10.1172/jci168649
BibTeX
@article{Han2024,
author = {Han, Dong and Labaf, Maryam and Zhao, Yawei and Owiredu, Jude and Zhang, Songqi and Patel, Krishna and Venkataramani, Kavita and Steinfeld, Jocelyn S and Han, Wanting and Li, Muqing and Liu, Mingyu and Wang, Zifeng and Besschetnova, Anna and Patalano, Susan and Mulhearn, Michaela J and Macoska, Jill A and Yuan, Xin and Balk, Steven P and Nelson, Peter S and Plymate, Stephen R and Gao, Shuai and Siegfried, Kellee R and Liu, Ruihua and Stangis, Mary M and Foxa, Gabrielle and Czernik, Piotr J and Williams, Bart O and Zarringhalam, Kourosh and Li, Xiaohong and Cai, Changmeng},
title = {Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {11},
doi = {10.1172/jci168649}
}
EUVIMED